Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C.

@article{Berenguer2006EfficacyPO,
  title={Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C.},
  author={M Molla Berenguer and Antonio Palau and Alberto Hernandez Fernandez and Salvador Benlloch and Victoria Aguilera and M E Herrero Prieto and Jos{\'e}-Miguel Ray{\'o}n and J. Iglesias Berenguer},
  journal={Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society},
  year={2006},
  volume={12 7},
  pages={1067-76}
}
There are unresolved issues regarding sustained virological response (SVR), tolerance and risk of rejection following antiviral therapy in liver transplantation (LT). The aim of our study was to determine efficacy, rejection risk and factors associated with SVR. HCV-infected LT patients with at least 6 months of follow-up following end-of-therapy (EOT) received combination therapy of ribavirin (Rbvr) + standard (n = 31)/pegIFN (n = 36) between 1999 and 2004 (95% genotype 1). An EOT and SVR was… CONTINUE READING